Press release
Treatment Resistant Depression Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Navitor Pharmaceuticals, Supernus Pharmaceuticals, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathwa
"Treatment Resistant Depression Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Treatment Resistant Depression Market.
The Treatment Resistant Depression Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Treatment Resistant Depression Pipeline Report: https://www.delveinsight.com/sample-request/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Treatment Resistant Depression treatment therapies with a considerable amount of success over the years.
• Treatment Resistant Depression companies working in the treatment market are GH Research Ireland Limited, atai Therapeutics, Inc., Beckley Psytech Limited, COMPASS Pathways, Mapreg, Sound Pharmaceuticals, Jiangsu Hansoh Pharmaceutical, Merck Sharp & Dohme, Novartis, Denovo Biopharma LLC, COMPASS Pathways, Navitor Pharmaceuticals, Supernus Pharmaceuticals, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others, are developing therapies for the Treatment Resistant Depression treatment
• Emerging Treatment Resistant Depression therapies in the different phases of clinical trials are- GH001, VLS-01-203 BU, BPL-003, Psilocybin, MAP4343, Ebselen, HS-10345, MK-1942, MIJ821, Liafensine, Psilocybin, NV5138, REL-1017, BPL-003, COMP360 (Psilocybin), AXS-05, FALKIERI (esketamine DPI), and others are expected to have a significant impact on the Treatment Resistant Depression market in the coming years.
• In March 2025, Beckley Psytech finalized subject enrollment for the core phase of its global Phase IIb trial evaluating BPL-003 (mebufotenin benzoate), a proprietary compound developed for treatment-resistant depression (TRD). The study is designed to assess the safety and effectiveness of single medium (8mg) and high (12mg) doses of the therapy compared to a sub-perceptual dose.
• In December 2024, LivaNova PLC (Nasdaq: LIVN), a leading medical technology company, announced that Brain Stimulation journal has published two key articles detailing data from the unipolar cohort of the RECOVER clinical trial. The studies assessed the safety and efficacy of LivaNova's VNS TherapyTM System in patients with treatment-resistant unipolar depression. Results showed that active vagus nerve stimulation (VNS) provided by the system significantly improved depressive symptoms, quality of life, and daily functioning compared to a sham (no-stimulation) group. The findings affirm VNS Therapy's clinical benefit and safety for individuals with treatment-resistant depression.
Treatment Resistant Depression Overview
Treatment-Resistant Depression (TRD) is a form of major depressive disorder that does not respond adequately to standard antidepressant treatments. Typically, TRD is diagnosed when a person fails to improve after trying at least two different antidepressants, each given at the right dose and duration. People with TRD may continue to experience persistent symptoms like low mood, fatigue, and loss of interest, and often require alternative therapies such as combination medications, psychotherapy, ketamine/esketamine, or neuromodulation treatments like electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS).
Get a Free Sample PDF Report to know more about Treatment Resistant Depression Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Treatment Resistant Depression Drugs Under Different Phases of Clinical Development Include:
• GH001: GH Research Ireland Limited
• VLS-01-203 BU: atai Therapeutics, Inc.
• BPL-003: Beckley Psytech Limited
• Psilocybin: COMPASS Pathways
• MAP4343: Mapreg
• Ebselen: Sound Pharmaceuticals
• HS-10345: Jiangsu Hansoh Pharmaceutical
• MK-1942: Merck Sharp & Dohme
• MIJ821: Novartis
• Liafensine: Denovo Biopharma LLC
• Psilocybin: COMPASS Pathways
• NV5138: Navitor Pharmaceuticals/Supernus Pharmaceuticals
• REL-1017: Relmada Therapeutics
• BPL-003: Beckley Psytech
• COMP360 (Psilocybin): COMPASS Pathways
• AXS-05: Axsome Therapeutics
• FALKIERI (esketamine DPI): Celon Pharma
Treatment Resistant Depression Route of Administration
Treatment Resistant Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type
Treatment Resistant Depression Molecule Type
Treatment Resistant Depression Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Treatment Resistant Depression Pipeline Therapeutics Assessment
• Treatment Resistant Depression Assessment by Product Type
• Treatment Resistant Depression By Stage and Product Type
• Treatment Resistant Depression Assessment by Route of Administration
• Treatment Resistant Depression By Stage and Route of Administration
• Treatment Resistant Depression Assessment by Molecule Type
• Treatment Resistant Depression by Stage and Molecule Type
DelveInsight's Treatment Resistant Depression Report covers around 25+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Treatment Resistant Depression product details are provided in the report. Download the Treatment Resistant Depression pipeline report to learn more about the emerging Treatment Resistant Depression therapies at:
https://www.delveinsight.com/sample-request/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Treatment Resistant Depression Therapeutics Market include:
Key companies developing therapies for Treatment Resistant Depression are - Navitor Pharmaceuticals, Supernus Pharmaceuticals, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others.
Treatment Resistant Depression Pipeline Analysis:
The Treatment Resistant Depression pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Treatment Resistant Depression with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Treatment Resistant Depression Treatment.
• Treatment Resistant Depression key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Treatment Resistant Depression Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Treatment Resistant Depression market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Treatment Resistant Depression drugs and therapies-
https://www.delveinsight.com/sample-request/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Treatment Resistant Depression Pipeline Market Drivers
• Increasing Prevalence of Treatment Resistant Depression increase in Research and Developmental activities for the treatment of Treatment Resistant Depression are some of the important factors that are fueling the Treatment Resistant Depression Market.
Treatment Resistant Depression Pipeline Market Barriers
• However, side-effects associated with the treatment of Treatment Resistant Depression, poor management of Treatment Resistant Depression and other factors are creating obstacles in the Treatment Resistant Depression Market growth.
Scope of Treatment Resistant Depression Pipeline Drug Insight
• Coverage: Global
• Key Treatment Resistant Depression Companies: GH Research Ireland Limited, atai Therapeutics, Inc., Beckley Psytech Limited, COMPASS Pathways, Mapreg, Sound Pharmaceuticals, Jiangsu Hansoh Pharmaceutical, Merck Sharp & Dohme, Novartis, Denovo Biopharma LLC, COMPASS Pathways, Navitor Pharmaceuticals, Supernus Pharmaceuticals, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others
• Key Treatment Resistant Depression Therapies: GH001, VLS-01-203 BU, BPL-003, Psilocybin, MAP4343, Ebselen, HS-10345, MK-1942, MIJ821, Liafensine, Psilocybin, NV5138, REL-1017, BPL-003, COMP360 (Psilocybin), AXS-05, FALKIERI (esketamine DPI), and others
• Treatment Resistant Depression Therapeutic Assessment: Treatment Resistant Depression current marketed and Treatment Resistant Depression emerging therapies
• Treatment Resistant Depression Market Dynamics: Treatment Resistant Depression market drivers and Treatment Resistant Depression market barriers
Request for Sample PDF Report for Treatment Resistant Depression Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Treatment Resistant Depression Report Introduction
2. Treatment Resistant Depression Executive Summary
3. Treatment Resistant Depression Overview
4. Treatment Resistant Depression- Analytical Perspective In-depth Commercial Assessment
5. Treatment Resistant Depression Pipeline Therapeutics
6. Treatment Resistant Depression Late Stage Products (Phase II/III)
7. Treatment Resistant Depression Mid Stage Products (Phase II)
8. Treatment Resistant Depression Early Stage Products (Phase I)
9. Treatment Resistant Depression Preclinical Stage Products
10. Treatment Resistant Depression Therapeutics Assessment
11. Treatment Resistant Depression Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Treatment Resistant Depression Key Companies
14. Treatment Resistant Depression Key Products
15. Treatment Resistant Depression Unmet Needs
16 . Treatment Resistant Depression Market Drivers and Barriers
17. Treatment Resistant Depression Future Perspectives and Conclusion
18. Treatment Resistant Depression Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Treatment Resistant Depression Market https://www.delveinsight.com/report-store/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Treatment Resistant Depression Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
Treatment Resistant Depression Epidemiology https://www.delveinsight.com/report-store/treatment-resistant-depression-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Treatment Resistant Depression Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
• Parp Poly Adp-ribose Polymerase Inhibitor Market: https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight
• Erectile Dysfunction Market: https://www.delveinsight.com/report-store/erectile-dysfunction-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market
• Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market
• Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Treatment Resistant Depression Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Navitor Pharmaceuticals, Supernus Pharmaceuticals, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathwa here
News-ID: 4064721 • Views: …
More Releases from DelveInsight Business Research
Global General Surgery Devices Market is expected to grow at a CAGR of 6.3% by 2 …
General Surgery Devices Market Overview
The Global General Surgery Devices Market is projected to grow at a CAGR of 6.34% from 2025 to 2032, driven by the rising burden of chronic diseases, increasing surgical interventions, and the adoption of robotic-assisted and minimally invasive techniques. Covering instruments such as handheld tools, electrosurgical devices, laparoscopic systems, wound closure products, and disposables, these devices play a critical role in diverse procedures, including orthopedic, cardiovascular,…
Intratumoral Cancer therapies Market Outlook 2034 - Clinical Trials, Market Size …
Intratumoral Cancer Market Summary
Intratumoral cancer therapies involve direct delivery into tumors, enabling localized targeting with minimal damage to surrounding tissue. Within the 7MM, non-melanoma cancers represent the largest share of cases and are expected to rise at ~2% annually, while in the US, breast cancer accounts for about 30% of cases with a growing incidence rate for intratumoral therapies. Currently, IMLYGIC is the only FDA-approved intratumoral therapy for melanoma, holding…
Bispecific and Trispecific Antibodies Market Projected to Experience Significant …
Bispecific antibodies represent an innovative class of therapies designed to address complex diseases by simultaneously binding two targets with a single molecule. Most currently approved bispecifics are for oncology, particularly multiple myeloma and diffuse large B-cell lymphoma (DLBCL). Beyond oncology, only HEMLIBRA and VABYSMO are approved for conditions such as hemophilia A, wet age-related macular degeneration, and diabetic macular edema, while KIMMTRAK is approved for uveal melanoma. The pipeline remains…
Narcolepsy Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Update …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Narcolepsy pipeline constitutes 10+ key companies continuously working towards developing 12+ Narcolepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Narcolepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for Treatment
Trigeminal Neuralgia Treatment Market Size, Trigeminal Neuralgia Treatment Marke …
Trigeminal Neuralgia Treatment Market Dynamics are clarified by an in-depth review of facts on current and emerging trends. To understand a resource, the paper uses Porter's five forces to examine the importance of numerous qualities such as understanding of suppliers and customers, dangers provided by various agents, competitive strength, and promising new businesses. precious. Furthermore, the study covers numerous firms' Trigeminal Neuralgia Treatment research data, benefit, gross margin, worldwide market…
Medical Tourism Market Report by Treatment Type (Dental Treatment, Cosmetic Trea …
The global medical tourism market accounted for $104.68 billion in 2019, and is projected to reach $273.72 billion by 2027, registering a CAGR of 12.8% from 2019 to 2027 in terms of value.
View Full Report: https://reports.valuates.com/market-reports/ALLI-Auto-0P310/medical-tourism
In terms of volume, the global medical tourism market accounted for 23,042.90 thousand patients in 2019, and is projected to reach 70,358.61 thousand patients by 2027, registering a CAGR of 15.0% from 2019 to…
Stretch Marks Treatment Market by Treatment & Forecast - 2025
Global Stretch Marks Treatment Market: Snapshot
In order to expand their outreach and add to their product portfolio, keen players in the global stretch marks treatment market are taking the inorganic route of acquisitions. They are also pouring money into development of new and better products.
Rising instances of obesity causing stretch marks is serving to catalyze growth in the market. In addition, growing aesthetic consciousness among people, especially among pregnant women,…
Stretch Marks Treatment Market by Treatment & Forecast - 2025
Global Stretch Marks Treatment Market: Snapshot
In order to expand their outreach and add to their product portfolio, keen players in the global stretch marks treatment market are taking the inorganic route of acquisitions. They are also pouring money into development of new and better products.
Rising instances of obesity causing stretch marks is serving to catalyze growth in the market. In addition, growing aesthetic consciousness among people, especially among pregnant women,…
Medical Tourism Market by Treatment Type (Dental Treatment, Cosmetic Treatment, …
Medical Tourism Market Overview:
The global medical tourism market was valued at $53,768 million in 2017, and is estimated to reach at $143,461 million by 2025, registering a CAGR of 12.9% from 2018 to 2025.
Organized travel across international borders to avail medical treatment of some form, which may or may not be available in the travelers home country is defined as medical tourism. Medical tourists travel abroad for the maintenance, enhancement,…
Substance Use Disorder Treatment Market By Type (Alcohol abuse treatment, Nicoti …
According to World Health Organization (WHO), the leading cause of disability around the world is not a physical disease, but a serious mood disorder known as depression. Around 350 million people suffer from depression worldwide, and that only about 50% of these individuals will ever receive treatment. According to Anxiety and Depression Association of America, in the U.S., over 15 million adults experience an episode of clinical depression in any…
